Psychedelic Medicine
December 30, 2025
Brian S. Barnett, Akhil Anand, Tatiana Falcone et al.
Objective: This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the United States using nationally representative data and to compare correlates of LSD use between lesbian, gay, and bisexual individuals (LGB) and heterosexual individuals. Method: Using National Survey on Drug Use and Health data on adults from 2015 to...
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
June 17, 2025
Clio E Franklin, Murat Altinay, Kala Bailey et al.
2 citations
Treatment-resistant mood disorders are often managed with intensive interventions that include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), ketamine, and esketamine, but the role of genetics in clinical response to those interventions is yet to be clearly determined. Here, we review the current literature on the genetics of response to these treatment modalities. To...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Rahul Katkar, Ashley M Perez, Murat Altinay et al.
4 citations
Gender-themed lysergic acid diethylamide (LSD) experiences have been documented anecdotally but not yet studied systematically. This study aimed to explore such experiences using data from Reddit to better understand their nature and potential therapeutic implications. In this retrospective observational study, posts and comments on the "r/LSD" subreddit reporting gender-themed LSD experiences...
JAMA Network Open
June 3, 2024
Manish Kumar Jha, Samuel T. Wilkinson, Kamini Krishnan et al.
29 citations
The ELEKT-D: Electroconvulsive Therapy (ECT) vs Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D) trial demonstrated noninferiority of intravenous ketamine vs ECT for nonpsychotic TRD. Clinical features that can guide selection of ketamine vs ECT may inform shared decision-making for patients with TRD. To evaluate whether selected clinical features were associated with...
New England Journal of Medicine
May 24, 2023
A. Anand, S. Mathew, Gerard Sanacora et al.
263 citations
BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain. METHODS We conducted an open-label, randomized, noninferiority trial involving patients referred to ECT clinics for treatment-resistant major depression. Patients with...
Psychiatric Annals
February 1, 2020
Hatice Guncu Kurt, Murat Altinay, Amit Anand
Patients who have not responded to two antidepressant trials in their current depressive episode are usually considered to have treatment-resistant depression (TRD). A detailed search on PubMed was conducted for reported response and remission rates for non-ketamine and ketamine treatments for TRD. From a variety of pharmacological and brain stimulation open-label studies, the treatments were...
Journal of Affective Disorders
2020
Roman M Dale, Kelly A. Bryant, Nora Finnegan et al.
17 citations
There are many putative mechanisms by which ketamine has its effect and many unanswered questions about risks and benefits of long-term ketamine therapy. A research imperative is the identification of predictors of response to intravenous ketamine, especially a sustained response to maintenance ketamine. Temperament is an inherited aspect of personality and is a predictive factor for outcome in...
Contemporary Clinical Trials
February 1, 2019
S. Mathew, S. Wilkinson, Murat Altinay et al.
54 citations
Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side effects. Ketamine has...